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Abstract 
Parkinson’s disease is the second most common neurodegenerative disorder. It is characterised by a typical 
movement disorder which occurs in part due to the selective degeneration of the dopaminergic neurons of the 
substantia nigra pars compacta. Current treatment for the motor disorder of Parkinson’s disease consists of 
dopaminergic medications, but these come with significant adverse effects, themselves an important part of the 
clinical course of Parkinson’s disease, particularly in the advanced stages. There is therefore a need for a treatment 
that is able to restore dopaminergic tone in the striatum in a physiological and targeted manner, such that these 
side effects are averted. A number of potential regenerative treatments have been developed with a view to 
achieving this. Following decades of optimisation and development, clinical trials of stem cell-based treatments 
and viral gene-delivery are on the horizon. In order for these treatments to be widely useful they must be clinically 
effective, cost-efficient, safe, and a number of practical aspects regarding storage and delivery of treatment, must 
be optimised. Whilst there have been many barriers to overcome, the field of regenerative medicine for 
Parkinson’s disease is now increasingly focussed on how these treatments will be delivered, demonstrating the 
significant progress that has been made, and the optimism surrounding these approaches. 
 
Key Points 
- Current treatments for Parkinson’s disease result in significant adverse effects due to non-targeted, non-
physiological delivery of dopamine 
- Cell-based and gene-delivery treatments offer a means of restoring dopamine to the striatum in Parkinson’s 
disease patients in a targeted manner 
- Several clinical trials of regenerative therapies are due to commence within the next two years 
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1. Introduction 
 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease [1]. 
It results in a typical movement disorder consisting of bradykinesia, rigidity, rest tremor, and as disease progresses, 
postural instability [1]. Additionally, there are a number of non-motor features such as cognitive impairment and 
dementia, neuropsychiatric symptoms (e.g. depression and anxiety), fatigue, anosmia and rapid-eye movement 
(REM)-sleep behaviour disorder [2]. The natural course of PD is one of gradual progression, with functional 
decline occurring over years [3]. 
 
The neuropathological hallmark of PD is the presence of Lewy bodies and Lewy neurites – intra-neuronal protein 
aggregates consisting largely of abnormal alpha-synuclein [4]. Whilst the non-motor features of PD occur due to 
neurodegeneration in the cerebral cortex and a number of brainstem nuclei, the movement disorder of PD primarily 
relates to the relatively selective degeneration of the neurons of the substantia nigra pars compacta [1, 5, 6]. These 
neurons produce the neurotransmitter dopamine, and deliver it to the striatum where it plays a crucial role in 
control of motor activity, as well as some cognitive processes. Treatment of the motor features of PD therefore, 
involves restoration of dopamine activity in the striatum. Current treatment options however, result in significant 
adverse effects which themselves constitute an important part of the illness that is experienced by the patient, 
particularly in the advanced stages of disease [1]. There is therefore much interest in development of novel 
therapies that are able to restore dopamine activity without development of these unwanted side effects. In this 
review we discuss progress towards these therapies, and their future prospects for the management of PD. 
 
 
2. Rationale for Regenerative Approaches in Parkinson’s Disease 
 
Current treatment of PD motor features generally involves the use of dopaminergic drugs. Most commonly, this 
involves administration of the dopamine precursor, levodopa, in combination with a peripheral dopa-
decarboxylase inhibitor to minimise peripheral side effects. Dopamine agonists or monoamine oxidase B 
inhibitors may be used in some patients, though as disease progresses, the majority require levodopa therapy. In 
the initial stages of levodopa treatment, most patients experience significant improvement in their motor problems 
and an improvement in function. However, with prolonged treatment, problematic adverse effects can have a 
significant impact on quality of life. These can include neuropsychiatric features such as hallucinations, thought 
to occur due to delivery of dopamine to extra-striatal brain regions (off-target effects). Patients may also develop 
disabling levodopa-induced dyskinesias – continuous involuntary movements which may affect the limbs, trunk 
or face. These motor effects are thought to occur due to the manner in which dopamine reaches the striatum 
following levodopa administration. Rather than occurring in a physiological pulsatile fashion, it is delivered 
continuously [7, 8]. Additionally, severe motor fluctuations may occur due to variations in the plasma 
concentration of levodopa and its transit across the blood-brain-barrier [9]. Sudden “off” spells can be particularly 
disabling for patients. There is therefore a currently unmet need to deliver dopamine specifically to the striatum, 
in a physiological manner, which is not achievable with current pharmacological agents. 
 
 
3. Cell Grafting for Parkinson’s Disease 
 
The movement disorder of PD largely results from a decline in the number and functional capacity of 
dopaminergic neurons in the substantia nigra. The onset of disease probably precedes the development of motor 
features by several years [2, 10, 11]. At the time of diagnosis therefore, significant neuronal loss has already 
occurred [12]. Restoration of a population of cells delivering dopamine to the striatum could theoretically allow 
for an improvement in motor abnormalities, without the development of the off-target and motor side effects 
associated with prolonged use of dopaminergic medication. 
 
A number of cell sources have been considered as potential options for grafting in PD. The first reports involved 
the grafting of autologous adrenal medullary cells (which release small amounts of dopamine) into the striatum 
[13, 14]. The initial reported positive results in these patients, despite only a short-period of follow-up, led to a 
number of patients receiving this type of graft [15-20]. However, it became clear that the recipients in fact 
experienced little clinical benefit, with a high incidence of psychiatric complications [21]. Furthermore, when 
these patients came to post-mortem it was found that the grafted cells had not survived [22]. 
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Around the same time there was interest in using foetal midbrains, which contain the developing nigral 
dopaminergic neurons, derived from terminated pregnancies as an alternative source of dopaminergic cells. After 
initial disappointing results in the first two patients [23], adjustments to the grafting procedure led to significant 
clinical benefits in a number of recipients, with some able to come off medication [24-27]. At post-mortem, these 
grafts have been shown to have survived for over two decades [28]. This suggested that cell-based approaches 
could indeed be useful for treating the movement disorder of PD, at least in some patients. However, enthusiasm 
was dampened following two sham-surgery controlled trials of foetal tissue grafts, in which little clinical benefit 
was observed, with several recipients developing graft-induced dyskinesias [29, 30]. Whilst these trials had 
several flaws in design, they highlighted the need for optimisation of the approach, in terms of the delivery method, 
the age and number of foetal midbrains used, the immunosuppressive regime, and the identification of a suitable 
recipient population, for example. A further trial was set up in Europe after analysis of the outcomes of the 
preceding foetal grafts, in which an optimised approach has been employed, with the aim of showing that cell-
based therapies for PD can be effective in appropriately selected patients 
(https://clinicaltrials.gov/ct2/show/NCT01898390). Eleven participants in this trial have now received grafts and 
are undergoing follow-up. However, even if shown to be effective, it has become clear that it will not be feasible 
to use this approach as a widespread treatment for PD, predominantly due to an inadequate supply of foetal tissue. 
 
A number of other cell sources have been investigated for grafting in PD, including porcine midbrain tissue, 
autologous carotid body cells, and retinal pigment epithelial (RPE) cells bound to microcarriers (Spheramine), 
with disappointing results (figure 1) [31-34]. Carotid body cells were investigated as a means of delivering glial-
derived neurotrophic factor (GDNF) to the striatum, which had appeared to be effective in animal models of PD 
[35]. Clinical effects however, were modest in human trials [32, 33]. RPE cells release small amounts of levodopa 
so have been investigated as a source of cells that could replenish striatal dopamine. However, in a sham-surgery 
controlled phase II trial, no benefit was demonstrated [31]. These approaches therefore did not offer any 
advantages over the use of foetal tissue, with which experience was building by this time. 
 
3.1. Stem Cell Treatments for Parkinson’s Disease 
 
Though the previous grafting trials have produced mixed results, the significant clinical benefit observed in some 
of the recipients of human foetal ventral mesencephalon grafts, has offered proof-of-concept that dopamine cell-
based therapies can be useful in PD. However, particularly given that PD is a common condition, a reliable source 
of dopaminergic cells is required for this approach to be widely useful – a condition that cannot be met by the 
unpredictable supply of foetal tissue. In contrast, this is potentially achievable through the use of stem cells to 
generate dopaminergic neural progenitor cells for grafting. Though other stem cell types have been purported as 
potential treatment options, there are two stem cell approaches in particular that might offer an effective treatment 
for the dopaminergic deficits of PD – embryonic stem cell (ESC)-derived and induced pluripotent stem cell 
(iPSC)-derived dopaminergic neural progenitor cells (figure 2) [36]. 
 
Human ESCs were first derived in 1998, opening up possibilities for development of regenerative therapies for a 
number of conditions, including PD [37]. ESCs are pluripotent cells derived from the inner cell mass of the early 
blastocyst, harvested from surplus human embryos from in vitro fertilisation procedures [36]. Generation of 
authentic dopaminergic neurons or their precursors however, has been challenging, and progress has been slow. 
In particular, whilst it was clear that ESCs could produce cells expressing tyroxine hydroxylase (the rate-limiting 
enzyme in dopamine synthesis) and that these could survive transplantation into rodents, the yield was highly 
variable [38-41]. Subsequent refinements of the differentiation protocols led to reports of ESC products that could 
not only survive grafting and integrate into the host, but could also produce a degree of functional recovery in pre-
clinical models [38-42]. 
 
A retrospective analysis of over 500 ESC-derived neural progenitor grafts into rats sought to identify factors that 
determined favourable graft outcome [43]. In this study it was found that high content of tyroxine hydroxylase-
positive cells were obtained in grafts enriched with neural progenitors expressing caudal midbrain markers, such 
as EN1 and CNPY1. However, the markers that had traditionally been used to signify dopaminergic fate (LMX1A, 
FOXA2, and OTX2), were found to not only be expressed in midbrain nigral progenitors, but also in the rostral 
midbrain subthalamic neuron progenitors, explaining the heterogeneity in graft outcome seen in prior studies [43]. 
Exposure to FGF8b at the later stages of the reprogramming protocol resulted in a high purity of neuronal 
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progenitors expressing markers of caudal midbrain patterning, which when grafted yielded a high content of 
dopaminergic neurons, and functional recovery [43]. This unexpected development in understanding means that 
it is now possible to generate ESC-derived neural progenitors which yield consistently high numbers of tyroxine 
hydroxylase-positive neurons, which could serve as the basis of a cell-replacement therapy. 
 
In 2007 conversion of human somatic cells to pluripotent stem cells was first reported, offering an alternative 
renewable source of cells that could serve as the basis of a regenerative therapy for PD [44, 45]. These iPSCs can 
also be differentiated into dopaminergic neural progenitors through similar differentiation protocols to those used 
with ESCs, potentially offering an alternative source for a cell-based therapy for PD, as has been shown recently 
in a primate model [46, 47].  
 
Each of these stem cell approaches has its own merits and drawbacks. Generation of ESC lines results in 
destruction of a viable human embryo, which of course results in ethical issues, though in most cultures the use 
of embryonic tissue that would otherwise be discarded is probably ethically favourable in comparison to the use 
of foetal tissue [48]. ESC-derived grafts would be allogeneic in nature, so would require a period of 
immunosuppression, and the associated risk of infection, malignancy and other adverse effects. The use of iPSCs 
does not carry these ethical implications, and can potentially be used to generate autologous grafts, derived from 
fibroblasts of the recipient, possibly circumventing the need for immunosuppressive treatment. However, 
heterogeneity in the response to a reprogramming protocol between individuals would mean that the cell product 
would vary between patients, with each product potentially being subject to regulatory approval and safety testing 
[36]. The more likely scenario is that investigators will need to prove that their reprogramming and differentiation 
processes are robust, yielding similar results for each patient, before an iPSC-derived product could be approved 
for clinical use. Generation of autologous iPSC-derived grafts is probably therefore prohibitively expensive for 
widespread use, at least in most current regulatory environments. Finally, with respect to autologous grafts, one 
should also consider the fact that the grafted cells will contain any PD genetic susceptibility factors carried by the 
patient, so may be at an increased risk of themselves succumbing to PD pathology – a situation that has been seen 
in some long-term surviving human foetal mesencephalon transplants [28]. 
 
One option that has been proposed is the generation of haplobanks, in which iPSC-lines could be derived from a 
number of individuals with specific homozygous HLA patterns, in order to provide coverage of a whole 
population. Whilst an appealing prospect, coverage of a national population through a haplobank would still 
require a large number of iPSC lines to be generated, all of which would be subject to safety testing and protocol 
optimisation, and the associated costs [36, 49]. Additionally, grafts delivered from a haplobanks would probably 
still warrant a period of immunosuppression, nullifying one of the main advantages of the iPSC approach over 
ESCs [36]. Whilst the use of haplobanks may not be a major advantage for transplantation into immune-privileged 
sites such as the brain, they may however confer a significant advantage in achieving transplantation of cell 
products to other organs. 
 
With both iPSC- and ESC-derived grafts, there is a theoretical risk of tumour formation, through graft overgrowth, 
aberrant differentiation of the grafted progenitors, or the presence of residual pluripotent cells in the graft, as is 
discussed further below. Though tumour formation occurred in some of the early pre-clinical in vivo studies [40, 
41, 50], developments in differentiation protocols have allowed for generation of refined cell products in which 
there are no residual pluripotent cells, and at least in animals, no tumour formation. 
 
In addition, bone marrow-derived mesenchymal stem cells have been investigated as a potential therapeutic option 
for PD. Whilst tyroxine hydroxylase-positive cells have been generated from mesenchymal stem cells [51], 
generation of midbrain dopaminergic neurons has not been achieved, so they are unlikely to be useful as a cell-
replacement therapy for PD[52]. Alternatively, it has been suggested that these cells may convey a neuroprotective 
effect through paracrine and anti-inflammatory properties [53, 54]. An open-label trial in a small group of PD 
patients demonstrated short-term safety of the use of these cells, but clinical effectiveness could not be 
demonstrated [55]. 
 
 
4. Gene Delivery Therapies for Parkinson’s Disease 
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An alternative approach towards a regenerative treatment for PD involves the use of viral vectors to deliver genes 
into the striatum. A number of virus-based gene-delivery therapies have now be investigated, some aiming to 
increase striatal dopamine [56-59], with potentially regenerative potential, and some aiming to convey a 
neuroprotective, potentially disease-modifying effect [60]. 
  
Two phase I trials have investigated the safety of adeno-associated virus (AAV) vectors delivering aromatic amino 
decarboxylase (AADC – the enzyme responsible for the conversion of levodopa to dopamine) into the putamina 
of PD patients [56, 57]. Both of these trials reported improvements in clinical and imaging parameters at six 
months. These procedures were reported to be well tolerated, though 30% of the subjects in one of the trials 
developed intracranial haemorrhages along the injection tract [56]. 
 
Following these initial trials, a phase I/II trial in France and the United Kingdom investigated the safety of a 
lentivirus gene therapy (ProSavin, Oxford Biomedica, United Kingdom) [58]. Lentiviruses have a capacity for a 
larger genetic cargo in comparison to AAV vectors, meaning that it was possible to deliver the genes encoding 
the other two rate-limiting enzymes in dopamine synthesis, tyrosine hydroxylase and cyclohydrolase-1, in addition 
to AADC. Whilst generally well-tolerated, 73% of recipients experienced an increase in on-medication 
dyskinesias in the first twelve months, which improved with a reduction in the levodopa dose. All patients 
demonstrated a significant improvement in the off-medication Unified Parkinson’s Disease Rating Scale 
(UPDRS) motor score at six months, with continued improvement over 48 months [58]. 
 
As well as targeting the dopamine synthesis pathway, AAVs have been used to deliver other genes to PD patients. 
A phase I trial in which the GDNF-like growth factor, neurturin, was delivered in an AAV vector, demonstrated 
that this approach was well-tolerated [60], though clinical outcomes in a follow-up sham-surgery controlled 
double-blind trial showed no benefit [61]. The glutamic acid decarboxylase gene has also been delivered using an 
AAV vector, with improvement in the UPDRS motor score being reported at six months compared to a sham-
surgery group [62], which persisted at 12 months [63]. 
 
 
5. Requirements for a Regenerative Therapy 
 
As has been discussed, the past few decades have seen significant progress towards a clinically useful regenerative 
therapy for PD. Some of the experimental techniques have shown initial promise in pre-clinical and early clinical 
trials, but have failed to live up to their expectations when tested in larger studies. Others, such as foetal midbrain 
grafts, appear to be effective in appropriately selected patients, but are not likely to be clinically useful for 
logistical and ethical reasons. A number of criteria must therefore be met if a regenerative therapy is to be useful 
going forward. 
 
Firstly, any potential future regenerative therapy must produce significant clinical benefit in the patient. In the 
case of the cell-based treatments that have been discussed, this relies on delivery of an adequate number of 
dopaminergic neuron precursors into the striatum. The graft must have a high purity of dopaminergic cells, and 
must receive signals from the host brain, so that dopamine is released in a physiological manner. Grafted cells 
must extend axons across sufficient distances to innervate the recipient striatum. Additionally, the grafted cells 
must survive for years in order for the patient to gain maximal benefit during the course of their disease. This 
includes a need to avoid rejection from the host immune system, and to avoid acquisition of pathology following 
grafting. Gene-delivery techniques must result in acquisition of dopamine-producing potential in a sufficient 
number of striatal cells to restore dopaminergic tone. As with potential cell-grafting therapies, the target cells of 
gene-delivery treatments must avoid acquisition of PD pathology, at least for a number of years, in order to provide 
significant clinical benefit. It is also important that any of these therapies does not result in significant extra-
striatal dopamine release, in order to retain the theoretical advantage over levodopa therapy. Finally the cell 
transplants must be free of a significant number of cells that could mediate adverse effects, such as the serotonergic 
neurons that may have been responsible for the graft-induced dyskinesias seen in some of the recipients of human 
foetal mesencephalon transplants [64, 65]. 
 
The second important consideration with regard to the utility of future regenerative therapies, is safety. These 
experimental treatments not only involve a neurosurgical procedure, which itself conveys a risk of intracranial 
haemorrhage, infection, and the risks associated with hospital admission, but are also associated with specific 
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safety concerns that must be addressed before they approach the clinic. With regard to stem cell-based treatments, 
the most significant concern is of potential tumour formation. Though tumour formation has not generally been 
seen in pre-clinical studies involving optimised reprogramming protocols, the risk of tumour formation after 
grafting into humans, in whom the graft will potentially be in situ for decades instead of the one or two years that 
it is present in a rodent or non-human primate, is not known. Unpublished spike-in experiments in which 
pluripotent cells were intentionally included in the graft have shown that tumour formation from residual 
pluripotent cells occurs early and at high frequency, so one would perhaps expect that if tumours are not observed 
over a period of a year in a rodent, that the risk of tumour formation from residual pluripotent cells will be non-
existent.  
 
In addition to the theoretical risk of tumour formation from residual stem cells, there is also potential for increased 
tumour risk due to acquisition of mutations in the grafted cells during cell culture, in which mutations that favour 
replication, or prevent apoptosis for example, provide a survival advantage over wild-type cells. For instance, it 
is clear that mutations in the tumour suppressor molecule P53 occur during cell culture, albeit at low frequency 
[66]. The risk that this poses in terms of de novo tumour formation following grafting is not known, particularly 
in view of the fact that mutations in these tumour suppressor genes may require a second-hit to herald neoplastic 
transformation. There is also doubt about the relevance of acquisition of oncogenic mutations that are associated 
with non-neuronal cancers, for example BRCA1 mutations, which are strongly associated with breast cancer, but 
are not seen in intracranial tumours. A planned Japanese clinical trial of iPSC-derived RPE cell transplants for 
age-related macular degeneration was halted after identification of a cancer-associated mutation in the cell product 
of the second patient [67]. Though there was no evidence of tumour formation with this cell product in animals, 
the risk that it posed to the potential recipient was difficult to interpret [68]. In view of this significant uncertainty 
about the implications of finding genetic abnormalities, there is variability in how upcoming clinical trials will 
screen for genetic aberrations in graft products, where some may perform whole genome sequencing, some may 
test for specific oncogenic mutations and some may test for karyotype anomalies only [69]. 
 
Delivery of genes using viral vectors is also associated with specific risks, and safety must be proven before they 
can be adopted in the clinic. The use of integrating vectors such as lentiviruses and gammaretroviruses can lead 
to insertional mutagenesis, with risk of transformation in the transfected cell [70]. Given that lentivirus gene 
therapies, such as ProSavin, target post-mitotic cells, the risk of malignant transformation is thought to be low, 
with no evidence of insertional mutagenesis in pre-clinical studies [58]. Lentiviral vectors are of low 
immunogenicity, so the impact of an intracranial host inflammatory response against the virus or transfected cells, 
is unlikely to be of clinical significance. 
 
Thirdly, any regenerative therapy must be ethically acceptable if it is to be employed widely [48]. Whilst the use 
of foetal tissue is particularly ethically contentious, the potential future therapies that have been discussed are 
generally considered to be less so, and are probably acceptable to most societies. Ethical barriers are unlikely 
therefore, to be a considerable challenge going forwards, although issues still exist with the use of human ESC-
derived products in some countries. 
 
Additionally, if these regenerative therapies will be widely used, it will be necessary for them to compete 
economically with current and other future treatments. In particular, these treatments will need to be comparable 
both in terms of efficacy and cost, with deep brain stimulation, and levodopa intestinal gel (Duodopa), both of 
which target the motor features of PD whilst minimising motor adverse effects [71, 72]. Furthermore, trials of 
novel multimodal drugs such as safinamide have demonstrated positive effects on motor function, with no increase 
in dyskinesia, providing another potential alternative to the regenerative therapies that have been discussed [73]. 
Whilst the cost of future regenerative therapies will be dependent on as yet undetermined manufacturing and 
marketing influences, the ultimate cost is likely to be similar to that of levodopa therapy and deep brain 
stimulation, and less than the current cost of Duodopa treatment, given the highly efficient differentiation 
protocols that now exist for making midbrain dopamine neuroblasts. 
 
Finally, a number of technical aspects must be addressed for any of these regenerative therapies to become widely 
useful. Procedures for freezing, storing, and thawing cell-based and virus-based products must be optimised and 
robust, and must not alter the properties of the treatment. Production of biological products must adhere to Good 
Manufacturing Practice regulations, which may require adjustments to the neurosurgical theatres in which these 
treatments will be delivered. However, whilst there are many issues still to be resolved, the focus of the field is 
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now increasingly shifting towards answering questions about the practicalities of how these treatments can be 
delivered, which highlights the progress that has been made over the past couple of decades. 
 
 
6. Characteristics of Suitable Patient Populations for Regenerative Therapies 
 
Clinical efficacy will depend on defining an appropriate patient population to target with regenerative therapies. 
It is becoming increasingly clear that PD encompasses a variety of clinical patterns, with some patients 
experiencing exclusively motor features, whilst others are at high risk of developing cognitive decline and 
dementia [3]. Some patients may be predisposed to the development of dyskinesias in comparison to others. The 
rate of functional decline differs considerably within the PD population. Regenerative therapies designed to 
increase striatal dopamine, and essentially replace the function of the nigral neurons that have already been lost, 
will theoretically be effective in patients whose predominant features are bradykinesia and rigidity. However, in 
patients with or at high risk of developing dementia, in whom the pathological correlate is more widespread Lewy 
body pathology and loss of extra-nigral neuronal populations [6], replenishing striatal dopamine will have limited 
effect on the clinical features that they have. Whilst there are emerging clinical markers of dementia risk including 
tau haplotype, and performance on specific cognitive tasks, success of regenerative therapies will in part be 
determined by the ability to accurately determine which patients are likely to benefit from these approaches [74]. 
 
One of the safety issues that arose in the randomised clinical trials of human foetal mesencephalon grafting was 
the high incidence of disabling graft-induced dyskinesias [29, 30]. However, graft recipients in these trials with 
pre-existing drug-induced dyskinesias were not excluded, and it is felt that appropriate selection of patients for 
future cell-based therapy trials, along with the use of cell products of increased purity and optimised grafting 
protocols, will circumvent this risk. However, exclusion of those with established pre-existing drug-induced 
dyskinesias will prevent the use of these approaches in a significant proportion of PD patients, and further work 
will be necessary to determine the population in which regenerative therapies can be used safely. An increase in 
dyskinesias was also observed in the ProSavin trial which highlights the need to determine the optimal approach 
for striatal dopamine delivery before these techniques are used widely [58]. 
 
 
7. Future Perspectives 
 
Since the first reports of the isolation and culturing of human ESCs two decades ago there have been steady 
progress towards a stem cell-based therapy that could be trialled in PD. This has warranted extensive in vitro 
optimisation of reprogramming protocols, as well as in vivo pre-clinical studies, which are ongoing. Many 
challenges have been overcome, including unexpected findings in neurodevelopmental biology, and the first in-
human trials of stem cell-derived dopaminergic neuron precursors are now on the horizon. 
 
Trials of ESC-derived dopaminergic neuron precursors are due to commence in the USA and in Europe over the 
next two years [64]. Additionally, a study of ESC-derived neural precursor cells is currently in the recruitment 
phase, sponsored by the Chinese Academy of Sciences (https://clinicaltrials.gov/ct2/show/NCT03119636). In 
Japan, trials of allogenic iPSC-derived neurons and autologous iPSC-derived neurons are expected to commence 
next year [69]. These trials will provide feasibility and tolerability data for stem-cell derived treatments, as well 
as early data about their clinical effectiveness. A follow-up trial of ProSavin in which an optimised gene-therapy 
product is to be investigated, is also due to commence this year. 
 
Viral-mediated direct conversion of somatic cells (e.g. fibroblasts) to generate induced neurons (iNs) also offers 
a potential source of dopaminergic neurons which could serve as a platform for a cell-based treatment for PD. 
This is a relatively novel technique, first described in 2010, which has a potential advantage over stem-cell based 
therapies in that there is no stem cell phase during reprogramming, theoretically reducing the risk of tumour 
formation [75]. However, it has not yet been possible to generate high purities of dopaminergic neurons, and the 
potential number of neurons produced is limited by the number of available somatic cells, which is in contrast to 
the renewable supply of neurons that can be derived from ESCs and iPSCs. iNs therefore do not currently offer a 
realistic approach to a useful cell-based therapy. One interesting concept associated with this direct conversion 
approach is the ability to generate dopaminergic neurons through in vivo reprogramming of host astrocytes [76]. 
Whilst this technique is a long way from being thought of as a potential therapeutic approach for PD, if safety can 
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be demonstrated and pure dopaminergic neuronal yields can be achieved, it may be considered for further 
investigation in the future. 
 
In addition to the experimental regenerative approaches that have been discussed, there is also much interest in 
development of therapies that could potentially slow or arrest disease progression. These putative treatments are 
designed to reduce the presence of aggregated alpha-synuclein, for example with novel immunological agents or 
repurposed drugs that enhance protein clearance mechanisms [71]. With a number of potential treatments 
currently in trials, the question is where will regenerative therapies fit into the future therapeutic approach to PD? 
Whilst it is possible that these alpha-synuclein reducing therapies may slow the progression of the motor and even 
cognitive aspects of PD, they will not restore the function of neurons that have already been lost. Given that 
significant neuronal loss occurs before the clinical diagnosis of PD, even with disease-modifying treatments many 
patients will still experience functional impairments due to the neuronal degeneration that has occurred in the 
prodromal and pre-diagnosis stage of disease. The regenerative therapies that have been discussed in this review 
aim to replace the function of the lost dopaminergic neurons, potentially restoring motor function to the pre-
morbid level, without the problematic adverse effects seen with current dopaminergic drugs. One could therefore 
envisage a landscape in which regenerative therapies are used to restore motor function in patients that have 
already accrued motor disability, in combination with alpha-synuclein reduction treatments to prevent disease 
progression, particularly in individuals at higher risk of cognitive symptoms. 
 
 
8. Concluding Remarks 
 
Since the early grafting trials for PD in the 1980s, significant progress has now been made towards effective and 
deliverable cell-based and gene delivery therapies for the motor disorder of PD. Over the coming decade these 
treatments will be investigated in the clinic, and it now seems likely that regenerative therapies will have a role in 
the management of PD in the medium-term future. Since the introduction of levodopa in the 1960s there have 
been few significant advances in the treatment of PD, but the regenerative approaches that have been discussed in 
this review, in combination with the emerging potentially disease-modifying approaches, provide optimism with 
regard to the future of regenerative treatments for PD. 
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Figure Legends 
 
Fig. 1 - Sources of potential and previously investigated regenerative treatments for Parkinson’s disease. Bold 
arrows indicate approaches that may offer deliverable treatment options, taking into account ethical, logistical, 
and regulatory factors. Abbreviations: ESC = embryonic stem cell, iPSC = induced pluripotent stem cell 
 
Fig. 2 – Stem cell therapies for Parkinson’s disease. Abbreviations: ESCs = embryonic stem cells, iPSCs = induced 
pluripotent stem cells 
 
 
 
 
 
